List view / Grid view
16 June 2011 | By Bristol-Myers Squibb Company
Bristol-Myers Squibb Company (NYSE: BMY) announced that the U.S. Food and Drug Administration (FDA) approved NULOJIX, the first selective T-cell costimulation blocker indicated for the prophylaxis of organ rejection in adult patients receiving a kidney transplant, in combination with basiliximab induction, mycophenolate mofetil (MMF), and corticosteroids.
5 June 2011 | By Bristol-Myers Squibb Company
Bristol-Myers Squibb Company (NYSE: BMY) today announced results from a second Phase 3 randomized, double blind study...
20 May 2011 | By Bristol-Myers Squibb Company
The European Commission has approved ELIQUIS® in the 27 countries of the EU...
25 March 2011 | By Bristol-Myers Squibb Company
For the Treatment of Patients with Newly Diagnosed or Previously-Treated Unresectable or Metastatic Melanoma, the Deadliest Form of Skin Cancer...
14 March 2011 | By Bristol-Myers Squibb Company
ACP Foundation’s initiative will address the U.S. HIV medical workforce shortage...
8 March 2011 | By AstraZeneca
The US FDA has accepted for review a New Drug Application (NDA) for dapagliflozin...
23 February 2011 | By AstraZeneca
The FDA has approved the inclusion of data from two clinical studies...
10 February 2011 | By Pfizer
Bristol-Myers Squibb Company and Pfizer Inc. announce the publication of their AVERROES study of apixaban in The New England Journal of Medicine...
18 November 2010 | By BUSINESS WIRE
Companies have discontinued the Phase 3 APPRAISE-2 clinical trial in patients...
18 November 2010 | By BUSINESS WIRE
For Up to $750 Million Aggregate Principal Amount of its Outstanding Debt Securities...
AstraZeneca and Bristol-Myers Squibb Company today announced that the US Food and Drug Administration (FDA) approved KOMBIGLYZE™ XR for the treatment of type 2 diabetes in adults. KOMBIGLYZE XR is the first and only once-a-day metformin extended-release (XR) plus dipeptidyl peptidase-4 (DPP-4) inhibitor combination tablet offering strong glycaemic control across…
21 June 2010 | By MacDougall Biomedical Communications
Saladax Biomedical, Inc. announced today that it has entered into a multi-year development & commercialization agreement with...
29 May 2009 | By
Much has been published elsewhere about the limitations of the compendial microbiological methods and the needs of current Pharmaceutical manufacturing, in particular related to the adoption of PAT as a quality tool1-4. Rapid Microbiology is seen by many as a tool for addressing a number of these limitations5,6. Rather less…
